IL-10 reduces rat brain injury following focal stroke

Neurosci Lett. 1998 Jul 31;251(3):189-92. doi: 10.1016/s0304-3940(98)00537-0.

Abstract

The effects of the anti-inflammatory cytokine, IL-10, on brain injury following permanent focal ischemia were determined. Rats subjected to occlusion of the right middle cerebral artery (MCAO) were administered IL-10 (1 microg) centrally into the lateral ventricle 30 min and 3 h post MCAO or systemically into the tail vein (5 or 15 microg/h) starting 30 min post MCAO for 3 h. Brains were removed 24 h later and infarct size was measured. IL-10 administered centrally significantly (P < 0.01) reduced infarct size by 20.7% +/- 6.0 compared to vehicle. Systemic IL-10 administration at 5 and 15 microg/h significantly (P < 0.05) decreased infarct size (40.3% +/- 14.0 and 30.7% +/- 13.7, respectively). These studies indicate that an anti-inflammatory therapeutic approach using IL-10 can provide neuroprotection in ischemic stroke.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / pharmacology*
  • Cerebral Infarction / etiology
  • Cerebral Infarction / pathology
  • Cerebral Infarction / prevention & control
  • Humans
  • Injections, Intravenous
  • Injections, Intraventricular
  • Interleukin-10 / administration & dosage
  • Interleukin-10 / pharmacology*
  • Ischemic Attack, Transient / complications
  • Ischemic Attack, Transient / pathology
  • Ischemic Attack, Transient / prevention & control*
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / pharmacology*
  • Rats
  • Rats, Inbred SHR
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / pharmacology

Substances

  • Anti-Inflammatory Agents
  • Neuroprotective Agents
  • Recombinant Proteins
  • Interleukin-10